U.K. officials and Vertex Pharmaceuticals (VRTX) have finally put to rest a years-long battle over access to cystic fibrosis treatments, which came to symbolize the growing clash between cash-strapped governments and the pharmaceutical industry over the cost of medicines.

The four-year deal calls for government reimbursement for a new triple-combination therapy, which has the potential to treat 90% of cystic fibrosis patients. In turn, the drug maker has agreed to provide evidence for the medication, along with two older treatments, to a cost-effectiveness watchdog agency. The pricing and timetable for Vertex to submit the data were not disclosed.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy